11 results match your criteria: "University Digestive Health Care Center Basel - Clarunis[Affiliation]"
Lancet Reg Health Eur
November 2024
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Background: Co-occurrence of inflammatory bowel disease (IBD) and type 1 diabetes (T1D) has been linked to poor clinical outcomes, but evidence on their bidirectional associations remain scarce. This study aims to investigate their bidirectional associations.
Methods: A nationwide matched cohort and case-control study with IBD patients identified between 1987 and 2017.
Eur Heart J Qual Care Clin Outcomes
August 2024
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Background: An increased risk of cardiovascular disease (CVD) has been reported in patients with diverticular disease (DD). However, there are knowledge gaps about specific risks of each major adverse cardiovascular event (MACE) component.
Methods: This nationwide cohort study included Swedish adults with DD (1987-2017, N=52,468) without previous CVD.
United European Gastroenterol J
October 2024
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Background: Microscopic colitis (MC) is an inflammatory disorder of the colon. To date, the relationship between inflammatory eye diseases and MC is unclear.
Objective: To assess whether inflammatory eye disease (iridocyclitis and episcleritis) is a risk factor for MC.
BMC Endocr Disord
June 2024
University Digestive Health Care Center Basel - Clarunis, Department of Visceral Surgery, St. Claraspital and University Hospital Basel, Basel, 4002, Switzerland.
Hepatol Commun
May 2024
Department of Biomedicine, Hepatology Laboratory, University and University Hospital Basel, Basel, Switzerland.
Background: Transarterial chemoembolization is the first-line treatment for intermediate-stage HCC. However, the response rate to transarterial chemoembolization varies, and the molecular mechanisms underlying variable responses are poorly understood. Patient-derived hepatocellular carcinoma organoids (HCCOs) offer a novel platform to investigate the molecular mechanisms underlying doxorubicin resistance.
View Article and Find Full Text PDFJ Hepatol
June 2024
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro, Sweden; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA.
Gut
October 2024
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Cardiovasc Diabetol
December 2023
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Background: Prior studies suggest a link between metabolic dysfunction-associated steatotic liver disease (MASLD) and incident arrhythmias, including atrial fibrillation (AF). However, robust data are lacking from cohorts with liver histology, which remains the gold standard for staging MASLD severity.
Methods: This population-based cohort included all Swedish adults with histologically-confirmed MASLD and without prior cardiac arrhythmias (1966-2016; n = 11,206).
Surg Endosc
October 2023
Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Background: Technical skill assessment in surgery relies on expert opinion. Therefore, it is time-consuming, costly, and often lacks objectivity. Analysis of intraoperative data by artificial intelligence (AI) has the potential for automated technical skill assessment.
View Article and Find Full Text PDFObes Surg
September 2023
University Digestive Health Care Center Basel - Clarunis, CH-4002, Basel, Switzerland.
Purpose: In the long term, laparoscopic sleeve gastrectomy (SG) may be associated with insufficient weight loss (IWL), gastroesophageal reflux disease (GERD), and persistence or relapse of associated medical problems. This study's objective is to present mid-term results regarding weight loss (WL), evolution of associated medical problems, and reoperation rate of patients who underwent a conversion after SG.
Methods: Retrospective single-center analysis of patients with a minimal follow-up of 2 years after conversion.